J Mov Disord 2019;12(3):139-151.
DOI: https://doi.org/10.14802/jmd.19046
In the original version of Table 1 associated with the review article “Modeling α-Synuclein Propagation with Preformed Fibril Injections”, the “amount of PFF injected” for the Rey et al. 2018 paper should be “0.8 μg of 5 mg/ml” instead of “8 μg 1 mg/ml”. The injection site mentioned in the “amount of PFFs injected” for Breid et al. 2016 paper should be “intraperitoneal” instead of “intramuscular”. The “amount of PFFs injected” for the Manfredsson et al. 2018 paper should be “6×5 μl” instead of “5 μg”. Additional information on the concentration of PFFs was added for Breid et al. 2016 paper and Durante et al. 2019 paper, being “1 μg/μl” and “1 mg/ml”, respectively.
Table 1.
Author | Year | Injection site | Duration/Time point | Model | Amount of PFFs injected |
---|---|---|---|---|---|
Luk et al. [20] | 2012 | Somatosensory cortex and dorsal neostriatum | 30 and 90 days post injection (p.i) | M83 mice maintained on a C57BL/C3H background, α-syn -/- mice maintained on a C57BL/6 background | 5 μg of 5 mg/mL human α-syn1-120Myc or WT full-length human α-syn per brain |
Luk et al. [18] | 2012 | Striatum | 30, 90, and 180 days p.i | C57BL6/C3H F1, C57BL6/SJL F1, and CD1 mice | 5 μg of 5 mg/mL full-length WT mouse α-syn per hemisphere |
Masuda-Suzukake et al. [40] | 2013 | Substantia nigra | 15 months p.i | 4- to 6-month-old female C57BL/6J mice | 10 µg of mouse or human α-syn PFFs |
Guo et al. [60] | 2013 | Hippocampus | 3, 6, and 9 months p.i | 2- to 3-month-old PS19 mice or C57BL6/C3H F1 mice | 5 μg of PFFs |
Sacino et al. [49] | 2014 | Hippocampus | 1, 2, and 4 months p.i | 2-month-old M83 mice and M20 mice | 2 μL of 2 mg/mL hfib 21–140 or Δ71–82 α-syn |
Sacino et al. [27] | 2014 | Intramuscular (biceps femoris) | 4, 8, and 12 months p.i | 2-month-old M83 mice and M20 mice | 10 μg of mouse PFFs, human 21–140 α-syn PFFs or Δ71–82 α-syn |
Paumier et al. [48] | 2015 | Striatum | 30, 60, and 180 days p.i | Adult male Sprague-Dawley rats | 8 μg of mouse or human α-syn PFFs |
Osterberg et al. [39] | 2015 | Cortex | 2, 3, and 4 months p.i | 2- to 3-month-old α-syn-GFP mice | 2.5 µL of 2 mg/mL mouse WT α-syn PFFs |
Peelaerts et al. [57] | 2015 | Substantia nigra | 4 months p.i | Female Wistar rats | 2 µL of 5 µg/µL α-syn PFFs (total of 10 µg) |
Breid et al. [30] | 2016 | Peritoneum, tongue | Up to 420 days p.i | Tg (M83+/−:Gfap-luc+/−) and (Gfap-luc+/−) mice | 5 μl (intraglossal) or 50 μl (intraperitoneal) of 1 ug/ul sonicated α-syn PFFs |
Kim et al. [59] | 2016 | Striatum | 3 and 6 months p.i | 3-month-old C57BL/6J mice | 5 μL of 10 μg/μL recombinant α-syn monomer, 2 μg/μL LPS(−) fibril seed, and 2 μg/μL LPS(+) fibril seed |
Thakur et al. [45] | 2017 | Substantia nigra, ventral tegmental area | 10 days p.i | Female Sprague-Dawley rats | 2.5 μL of full-length recombinant human α-syn PFFs (10 μg total) per site |
Karampetsou, et al. [21] | 2017 | Striatum | 60 days p.i | 2- to 4-month-old male and female wild-type C57BL6/C3H mice and α-Syn-/- mice (C57BL6/JOlaHsd mice) | 4.25 μg (4 μL) of three different types of human recombinant fibrillar α-syn |
Abdelmotilib et al. [35] | 2017 | Striatum | 6 months p.i | 8- to 10-week-old mice and rats | 10 μg (mice) or 20 μg (rats) of mouse or human α-syn PFFs |
Blumenstock et al. [43] | 2017 | Dorsal striatum | 30, 60, and 90 days p.i; 5 and 9 months p.i | 2-month-old mice | 5 μL (25 μg) of mouse α-syn PFFs |
Sorrentino et al. [56] | 2017 | IC or CPu | 4–5 months p.i | 4-month-old M20 non-Tg (NTG) mice | 2 μL of 2 mg/mL human or mouse WT α-syn PFFs |
Harms et al. [63] | 2017 | Substantia nigra | 1, 3, and 6 months p.i | 8- to 10-week old Sprague-Dawley rats | 8 μg of mouse α-syn PFFs |
Shimozawa et al. [50] | 2017 | Caudate and putamen | 3 months p.i | 26-month-old marmosets | 50 μL aliquots of 4 mg/mL mouse α-syn PFFs |
Okuzumi et al. [44] | 2018 | Striatum | 1 week pi, 0.75, 1.5, 3, and 6 months p.i | 2- to 3-month-old C57BL/6J mice | 5 μg/2.5 μL of recombinant mouse or human α-syn PFFs |
Rey et al. [29] | 2018 | Olfactory bulb | 1, 2, 3, 6, 9, 12, 18, and 23 months p.i | 3-month-old female C57BL/6J mice | 0.8 μl of 5 mg/ml WT mouse or human α-syn PFFs |
Uemura et al. [28] | 2018 | Mouse gastric wall | 45 days p.i | 2-month-old male C57BL/6J mice | 3 μL of 2 μg/μL mouse α-syn PFFs |
Duffy et al. [47] | 2018 | Striatum | 6 months p.i | 2-month-old male Fischer mice | 2 μL of 2 μg/μL mouse α-syn PFFs (unilateral) |
Sorrentino et al. [42] | 2018 | Muscle | 1, 2, 3, and 4 months p.i | 2-month-old M83+/- mice | 2,5, or 10 μg of mouse α-syn fibrils |
Milanese et al. [41] | 2018 | Striatum | 4 months p.i | C57BL/6 mice | 5 μg (2.5 μL) of human α-syn PFFs |
Terada et al. [46] | 2018 | Striatum | 3 months p.i | 10-week-old C57BL/6J mice | 5 μL (150 μM) of human WT |
Milanese et al. [41] | 2018 | Striatum | 4 months p.i | C57BL/6 mice | 5 μg (2.5 μL) of human α-syn PFFs |
Terada et al. [46] | 2018 | Striatum | 3 months p.i | 10-week-old C57BL/6J mice | 5 μL (150 μM) of human WT or truncated α-syn PFFs |
Ayers et al. [54] | 2018 | Sciatic nerve (unilateral) | 1, 2, and 4 months p.i and end-stage | M83 and M20 mice | 2 μL of 2 mg/mL mouse WT or human Δ71–82 α-syn PFFs |
Manfredsson et al. [55] | 2018 | Enteric neurons of the descending colon | 1, 6, and 12 months p.i | Young adult male Sprague-Dawley rats | 6×5 µl of 2 μg/μl mouse or human α-syn PFFs |
Manfredsson et al. [55] | 2018 | Colon and stomach | 12 months p.i | Non-human primates (Macaca fascicularis) | 10 injections of 10 µL (2 µg/µL) |
Peralta Ramos et al. [68] | 2019 | Vein | 12 hours p.i | 2-month-old C57BL/6 mice | 5 μg of Atto 488-labeled α-syn fibrils or ribbons |
Durante et al. [77] | 2019 | Striatum | 6, 7 weeks p.i | Male Wistar rats | 1 µL of 1 mg/ml human α-syn PFFs per site |
The table describes the sites of preformed fibril (PFF) injection, the ages of the animals, the amount of seed, and the duration or time points sample analysis used in the experiments. WT: wild type, GFP: green fluorescent protein, LPS: lipopolysaccharide, IC: inferior colliculus, CPu: caudate putamen, NTG: non-Tg.
In the first paragraph of the “SYNUCLEINOPATHIES IN PERIPHERAL PFF INJECTION MODELS” section, we included the description olfactory bulb injection. However, this content belongs to the “SYNUCLEINOPATHIES IN INTRACEREBRAL PFF INJECTION MODELS” section.